1 / 19

Heidi M. Soeters, Sonia Napravnik , Monita Patel, Joe Eron , Annelies Van Rie

The effect of tuberculosis treatment on virologic and CD4 cell count response to combination antiretroviral therapy: a systematic review and meta-analysis. Heidi M. Soeters, Sonia Napravnik , Monita Patel, Joe Eron , Annelies Van Rie 44 th Union World Conference – Abstract OP-188-02

xia
Télécharger la présentation

Heidi M. Soeters, Sonia Napravnik , Monita Patel, Joe Eron , Annelies Van Rie

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The effect of tuberculosis treatment on virologic and CD4 cell count response to combination antiretroviral therapy: a systematic review and meta-analysis Heidi M. Soeters, Sonia Napravnik, Monita Patel, Joe Eron, Annelies Van Rie 44th Union World Conference – Abstract OP-188-02 November 2, 2013

  2. Introduction

  3. Introduction • In 2010, the World Health Organization (WHO) recommended that all people living with HIV (PLWH) with TB be initiated on combination antiretroviral therapy (cART), regardless of CD4 count1 • Goal of 100% cART coverage of co-infected patients by 20152 • Many individuals have been and will be initiating cART while concurrently on TB treatment WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010. WHO and Stop TB Partnership. The Global Plan to Stop TB 2011-2015. 2010.

  4. Introduction • PLWH also on TB treatment may experience a differential response to cART due to: • Drug-drug interactions • Increased risk of drug toxicity • Immune reconstitution inflammatory syndrome (IRIS) • Lower adherence due to high pill burden

  5. Introduction • The effect of TB treatment on a patient’s response to cART has not been fully elucidated and requires careful evaluation • Study aim: Systematic review and meta-analysis of the effect of receiving TB treatment at the time of cART initiation on virologic and CD4 count response among HIV-infected adults

  6. Research Methods

  7. Literature Review • Systematic search of PubMed, EMBASE, and 2009 – 2012 conference abstracts • “HIV AND Tuberculosis AND (Viral Load OR CD4 lymphocyte count OR mortality) AND Antiretroviral therapy” • Citation lists, reviews, & Web of Science citation searches • Human subjects research published since 1997

  8. Study Selection • Eligible studies: • Included antiretroviral-naïve HIV-infected adults initiating cART • Some were receiving TB treatment at cART initiation, some were not receiving TB treatment • Reported virologic and/or CD4 count response to cART • Outcome stratified by TB treatment status • Excluded: studies with children <14 years

  9. Meta-analytic methods • Calculated the method of moments estimate of the between-study variance (τ2) • Used τ2 and random-effects summarization using unconditional variances to calculate relative risks (RRRE) • P-values for standard chi-square homogeneity test statistic were used to assess overall consistency among the effect estimates

  10. Results

  11. Results • 25 eligible cohort studies reported data on 49,578 adults • 8,826 (18%) were receiving TB treatment at cART initiation • 17 virologic response; 21 CD4 count response • Most from sub-Saharan Africa, 9 from Asia, 3 from Europe/North America

  12. Results: Virologic Suppression

  13. Results: Virologic Suppression • Meta-regression • No effect of suppression definition (<50 vs. <400) • No effect of type of cART regimen

  14. Results: Virologic Failure • Virologic failure (7 studies) • Much heterogeneity in outcome measures • HIV RNA levels of >5000 copies/mL • Failed to suppress <400 copies/mL • Rebounded after being previously undetectable or never became undetectable • Time to first value ≥400 • Time to 2 consecutive values ≥5000 copies/mL • Time to first value >500 among those who initially suppressed • Heterogeneity precluded formal meta-analysis

  15. Results: CD4 count response

  16. Conclusions

  17. Conclusions • TB treatment did not increase risk of virologic suppression at 1 to 48 months following cART initiation among adults • Could not make formal meta-analytic conclusions regarding the effect of TB treatment on virologic failure or CD4 count response, but review of the literature suggests: • TB treatment does not appear to affect virologic rebound • TB treatment is associated with lower CD4 counts at cART initiation and during follow-up, but comparable increase in CD4 count • Standardization of reported outcomes is needed to facilitate future between-study comparisons • Studies reporting cART regimen-specific estimates would further improve our knowledge

  18. Acknowledgements • Mellanye Lackey • Harry Moultrie • Alan Brookhart

  19. Thank you!Questions?

More Related